Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Malaria Parasitemia and Parasite Density in Antiretroviral-Treated HIV-Infected Adults Following Discontinuation of Cotrimoxazole Prophylaxis.

Ottichilo RK, Polyak CS, Guyah B, Singa B, Nyataya J, Yuhas K, John-Stewart G, Waitumbi JN.

J Infect Dis. 2017 Jan 1;215(1):88-94. doi: 10.1093/infdis/jiw495.

PMID:
28077587
2.

A Systematic Review of the Incidence, Risk Factors and Case Fatality Rates of Invasive Nontyphoidal Salmonella (iNTS) Disease in Africa (1966 to 2014).

Uche IV, MacLennan CA, Saul A.

PLoS Negl Trop Dis. 2017 Jan 5;11(1):e0005118. doi: 10.1371/journal.pntd.0005118.

3.

Antiretroviral therapy improves survival among TB-HIV co-infected patients who have CD4+ T-cell count above 350cells/mm3.

Mutembo S, Mutanga JN, Musokotwane K, Alisheke L, Whalen CC.

BMC Infect Dis. 2016 Oct 17;16(1):572.

4.

Act local, think global: how the Malawi experience of scaling up antiretroviral treatment has informed global policy.

Harries AD, Ford N, Jahn A, Schouten EJ, Libamba E, Chimbwandira F, Maher D.

BMC Public Health. 2016 Sep 6;16:938. doi: 10.1186/s12889-016-3620-x.

5.

Epidemiology of Tuberculosis in Malawi.

Nyirenda T.

Malawi Med J. 2006 Sep;18(3):147-59. No abstract available.

6.

Epidemiology of HIV/AIDS in adults in Malawi.

Geubbels E, Bowie C.

Malawi Med J. 2006 Sep;18(3):111-33. No abstract available.

7.

Changes in Escherichia coli resistance to co-trimoxazole in tuberculosis patients and in relation to co-trimoxazole prophylaxis in Thyolo, Malawi.

Zachariah R, Harries AD, Spielmann MP, Arendt V, Nchingula D, Mwenda R, Courtielle O, Kirpach P, Mwale B, Salaniponi F.

Malawi Med J. 2002 Sep;14(2):10-2.

8.

TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial.

Laurens MB, Mungwira RG, Nyirenda OM, Divala TH, Kanjala M, Muwalo F, Mkandawire FA, Tsirizani L, Nyangulu W, Mwinjiwa E, Taylor TE, Mallewa J, Blackwelder WC, Plowe CV, Laufer MK, van Oosterhout JJ.

Trials. 2016 Jul 18;17(1):322. doi: 10.1186/s13063-016-1392-3.

9.

Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.

Alsaad N, Dijkstra JA, Akkerman OW, de Lange WC, van Soolingen D, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3942-7. doi: 10.1128/AAC.02175-15.

10.

Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority Trial.

Polyak CS, Yuhas K, Singa B, Khaemba M, Walson J, Richardson BA, John-Stewart G.

PLoS Med. 2016 Jan 5;13(1):e1001934. doi: 10.1371/journal.pmed.1001934.

11.
12.

Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections.

Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM.

Clin Microbiol Rev. 2015 Oct;28(4):901-37. doi: 10.1128/CMR.00002-15. Review.

13.

Trends in prevalence of diarrhoea, Kaposi's sarcoma, bacterial pneumonia, malaria and geohelminths among HIV positive individuals in Uganda.

Rubaihayo J, Tumwesigye NM, Konde-Lule J.

AIDS Res Ther. 2015 Jun 13;12:20. doi: 10.1186/s12981-015-0060-0.

14.

Quality of the antibiotics--amoxicillin and co-trimoxazole from Ghana, Nigeria, and the United Kingdom.

Fadeyi I, Lalani M, Mailk N, Van Wyk A, Kaur H.

Am J Trop Med Hyg. 2015 Jun;92(6 Suppl):87-94. doi: 10.4269/ajtmh.14-0539.

15.

Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China.

Cheng W, Wu Y, Wen Y, Ma Y, Zhao D, Dou Z, Zhang W, Bulterys M, Zhang F.

Bull World Health Organ. 2015 Mar 1;93(3):152-60. doi: 10.2471/BLT.14.142745.

16.
17.

Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challenge.

Bisson GP, Zetola N, Collman RG.

Curr HIV/AIDS Rep. 2015 Mar;12(1):107-16. doi: 10.1007/s11904-015-0256-x. Review.

18.

Assessment of the impact of cotrimoxazole prophylaxis on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review.

Saadani Hassani A, Marston BJ, Kaplan JE.

J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3:S257-69. doi: 10.1097/QAI.0000000000000486. Review. Erratum in: J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):e84.

19.

Effect of cotrimoxazole prophylaxis on malaria occurrence in HIV-infected patients on antiretroviral therapy in sub-Saharan Africa.

Kasirye R, Baisley K, Munderi P, Grosskurth H.

Trop Med Int Health. 2015 May;20(5):569-580. doi: 10.1111/tmi.12463. Review.

20.

Timing, rates, and causes of death in a large South African tuberculosis programme.

Field N, Lim MS, Murray J, Dowdeswell RJ, Glynn JR, Sonnenberg P.

BMC Infect Dis. 2014 Dec 21;14:3858. doi: 10.1186/s12879-014-0679-9.

Supplemental Content

Support Center